DYADIC INTERNATIONAL INC Q4 FY2024 earnings call

Key Points - Strategic focus on near-term product commercialization and technology licensing. - Utilization of C1 and Dapavas microbial protein production platforms for alternative proteins, life sciences, and bio-industrials. - Partnerships with CEPI, Gates Foundation, and others to accelerate vaccine and treatment development. - Progress in commercializing non-pharmaceutical products like recombinant human albumin, transferrin, and dairy enzymes. - Advancement of biopharmaceutical pipeline through development of antigens, antibodies, etc., for human and animal health.

In 2024, Dyadic generated $3.495 million in revenue. Milestone and license payments totaled $1.9 million. The company's product segments included alternative proteins (e.g., recombinant human albumin, transferrin, alpha-lactalbumin), life sciences (e.g., DNA and RNA-related reagent enzymes like RNase-free DNase I), and bio-industrials (e.g., enzyme cocktails like ENDSRIZYG for converting agricultural residues to fermentable sugars). The alternative proteins segment drove near-term focus and revenue, with non-pharmaceutical products like cell culture media components and dairy enzymes showing progress.

Forward-Looking Statements - Plan to launch first commercial products in 2025, including recombinant albumin, non-animal dairy products, and DNase I. - Expand strategic partnerships across alternative protein, diagnostics, and research tools segments. - Continue leveraging C1 and Dapavas platforms to meet global demand for efficient biomanufacturing technologies.

Risks - Uncertainties related to regulatory hurdles for commercializing biopharmaceutical products. - Market adoption challenges for new alternative protein and bio-industrial products. - Volatility in funding for grants and partnerships that could impact development timelines.

Q: How do the Gates Foundation and CEPI grants fit into Dyadic's strategy?

A: Mark Emalfarb stated that Gates and CEPI grants drive innovation and advancement of the C1 platform, with CEPI grant supporting recombinant protein vaccine development and Gates grant supporting cell line development for monoclonal antibodies.

Q: What are the steps to commercialize dairy enzymes?

A: Joseph Hazelton mentioned that dairy enzymes require processes like GRAS application in the US and regulatory oversight in the EU, including scaling up, proving quality, and ensuring food-grade production.

Q: What is the market size opportunity for Dyadic's products?

A: Joseph Hazelton noted markets like human albumin ($5.6B growing), DNase I/RNA enzymes ($900M growing), and non-animal dairy proteins ($26B), highlighting high-value segments for Dyadic's technology.